[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 6 of about 6
1. Alebouyeh M, Moussavi F, Tabari AK, Vossough P: Aggressive intra-abdominal fibromatosis in children and response to chemotherapy. Pediatr Hematol Oncol; 2005 Sep;22(6):447-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intra-abdominal fibromatosis (IAF) is a rare benign neoplasm arising from the abdominal fibrous tissue, mostly in the mesentery.
  • The authors report on a boy who presented with a large IAF at the age of 5 years.
  • Within 6 months after initial presentation, he underwent 4 subsequent abdominal explorations for diagnosis, tumor reduction, and intestinal obstructions.
  • IAF was confirmed by the presence of vimentin and absence of other biological cell markers.
  • Due to accelerated tumor growth and deteriorated general condition, as a last resort, a chemotherapy trial with vincristin and methotrexate was carried out.
  • This regimen proved to be effective in reducing the tumor burden and improving the patient's general condition.
  • Outcome of IAF depends on early diagnosis and complete tumor resection, and, if indicated, timely employment of neo/adjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Fibromatosis, Abdominal / drug therapy. Fibromatosis, Aggressive / drug therapy
  • [MeSH-minor] Child, Preschool. Humans. Male. Methotrexate / administration & dosage. Tumor Burden / drug effects. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Aggressive Fibromatosis.
  • Genetic Alliance. consumer health - Fibromatosis.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16169811.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


2. Majeski J: Endoscopic capsule retention in an intestinal anastomosis. Int Surg; 2009 Jul-Sep;94(3):254-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic capsule retention in an intestinal anastomosis.
  • Wireless capsule endoscopy (CE) was introduced for human clinical diagnostic utilization in 2001.
  • CE has become a first line method of evaluating the small intestine for suspected abnormalities and disease.
  • Contraindications to CE include the presence of intestinal obstruction, fistulas, or structures.
  • Capsule retention has been reported in patients with a strictured or stenotic area of intestine caused by occult neoplasm, nonsteroidal anti-inflammatory drugs, Crohn's disease, radiation enteritis, or previous abdominal surgery.
  • Safe and effective use of CE has been reported in the evaluation of patients who have previously undergone surgical resection of the small intestine for benign or malignant disease.
  • This case report reviews the utilization and subsequent retention of an endoscopic capsule in a symptomatic patient who had a previous small bowel resection caused by the sequelae of radiation therapy to the abdomen and pelvis for endometrial cancer.
  • The resected segment of small intestine contained the endoscopic capsule, previous intestinal anastomosis, recurrent bowel strictures secondary to radiation enteritis, and a chronic ulcerated intestinal lumen caused by the retained endoscopic capsule.
  • This case report shows that use of CE cannot always be considered safe in patients who have had a previous surgical intestinal anastomosis.
  • CE should not be used in patients who have had a previous small bowel resection and anastomosis for symptomatic intestinal structures that developed because of radiation enteritis.
  • [MeSH-major] Capsule Endoscopy / adverse effects. Endometrial Neoplasms / surgery. Foreign Bodies / complications. Foreign Bodies / surgery. Intestinal Obstruction / etiology. Intestinal Obstruction / surgery. Intestine, Small / surgery

  • MedlinePlus Health Information. consumer health - Foreign Bodies.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20187521.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


3. Wang PH, Lee WL, Chao HT, Yuan CC: Disseminated carcinomatosis after laparoscopic surgery for presumably benign ruptured ovarian teratoma. Eur J Obstet Gynecol Reprod Biol; 2000 Mar;89(1):89-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated carcinomatosis after laparoscopic surgery for presumably benign ruptured ovarian teratoma.
  • The authors reported the intraperitoneal carcinomatosis after laparoscopic surgery for presumably benign ruptured ovarian teratoma in a 28-year-old woman.
  • Evidence demonstrated intestinal obstruction associated with ascites after a detailed evaluation.
  • All tumor evaluations including tumor markers, a thorough physical examination, imaging studies and evaluations of the nuclear medicine were negative except of intraperitoneal carcinoma, origin to be determined.
  • [MeSH-major] Carcinoma, Squamous Cell / etiology. Laparoscopy / adverse effects. Ovarian Neoplasms / surgery. Peritoneal Neoplasms / etiology. Teratoma / surgery
  • [MeSH-minor] Adult. Fatal Outcome. Female. Humans. Neoplasm Seeding. Rupture, Spontaneous

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10733031.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] IRELAND
  •  go-up   go-down


Advertisement
4. Paulino AC, Wen BC, Brown CK, Tannous R, Mayr NA, Zhen WK, Weidner GJ, Hussey DH: Late effects in children treated with radiation therapy for Wilms' tumor. Int J Radiat Oncol Biol Phys; 2000 Mar 15;46(5):1239-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late effects in children treated with radiation therapy for Wilms' tumor.
  • PURPOSE: To determine the frequency and types of late effects in children receiving radiation therapy (RT) for Wilms' tumor.
  • MATERIALS AND METHODS: From 1968 to 1994, 55 children received megavoltage RT at our institution as part of treatment for Wilms' tumor.
  • There were 12 Stage I, eight Stage II, 15 Stage III, six Stage IV, and one Stage V patient.
  • All patients received chemotherapy; the most common agents were actinomycin-D/vincristine/adriamycin in 13 and actinomycin-D/vincristine in 18.
  • Four patients developed benign neoplasms; three were in the RT field (two osteochondroma, one lipoma) and one outside (cervical intraepithelial neoplasia II).
  • CONCLUSIONS: Late effects of therapy were seen in more than two thirds of children treated for Wilms' tumor.
  • [MeSH-major] Kidney Neoplasms / radiotherapy. Radiation Injuries / complications. Wilms Tumor / radiotherapy
  • [MeSH-minor] Child. Child, Preschool. Dose-Response Relationship, Radiation. Female. Fertility / radiation effects. Follow-Up Studies. Humans. Infant. Intestinal Obstruction / etiology. Intestine, Small / radiation effects. Kidney Diseases / etiology. Kyphosis / etiology. Male. Muscles / radiation effects. Neoplasm Staging. Neoplasms, Second Primary / etiology. Puberty, Delayed / etiology. Scoliosis / etiology. Time Factors


5. Fukuta N, Kitano M, Maekawa K, Chikugo T, Kudo M: Estimation of the malignant potential of gastrointestinal stromal tumors: the value of contrast-enhanced coded phase-inversion harmonics US. J Gastroenterol; 2005 Mar;40(3):247-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimation of the malignant potential of gastrointestinal stromal tumors: the value of contrast-enhanced coded phase-inversion harmonics US.
  • BACKGROUND: Recently, contrast agents for ultrasonography (US) such as Levovist have been introduced for routine clinical use.
  • The contrast-enhanced US with Levovist permits evaluation of the intratumoral vascularity of hepatic and pancreatic tumors and is useful for their differential diagnosis.
  • The purpose of the present study was to assess tumor vessels and the parenchymal flow of gastrointestinal stromal tumors (GISTs) by contrast-enhanced coded phase-inversion harmonic US and to evaluate whether vascularity is related to the malignant grade of the GISTs.
  • Tumors were observed in a real-time fashion of contrast-enhanced coded phase-inversion harmonic US after the injection of Levovist (400 mg/ml).
  • The vascular patterns were compared with tumor size, histological diagnosis, KIT mutations, and clinical findings such as metastasis.
  • RESULTS: The contrast-enhanced US images of the GISTs were classified into two types according to the blood flow area of the tumors as seen by real-time continuous imaging of the tumor vessels.
  • The image pattern "Poor" represented vessels flowing only in the peripheral part of the tumor, and "Rich" represented abundant vessels flowing from the periphery to the central part of the tumor.
  • Based on the final diagnosis, all tumors with "Poor" images were determined to be benign GISTs, and the rest tumors except one with "Rich" images were determined to be malignant GISTs.
  • [MeSH-major] Contrast Media. Gastrointestinal Stromal Tumors / blood supply. Neovascularization, Pathologic / ultrasonography. Polysaccharides
  • [MeSH-minor] Blood Flow Velocity / physiology. DNA, Neoplasm / genetics. Female. History, 17th Century. History, 18th Century. Humans. Infant, Newborn. Injections, Intravenous. Intestinal Mucosa / immunology. Intestinal Mucosa / pathology. Male. Microbubbles. Mutation. Neoplasm Staging / methods. Polymerase Chain Reaction. Proto-Oncogene Proteins c-kit / genetics. Retrospective Studies. Severity of Illness Index

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Gastroenterol. 2005 Mar;40(3):320-1 [15830297.001]
  • (PMID = 15830283.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Historical Article; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Contrast Media; 0 / DNA, Neoplasm; 0 / Polysaccharides; 127279-08-7 / SHU 508; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


6. Radulescu S, Ridgway RA, Appleton P, Kroboth K, Patel S, Woodgett J, Taylor S, Nathke IS, Sansom OJ: Defining the role of APC in the mitotic spindle checkpoint in vivo: APC-deficient cells are resistant to Taxol. Oncogene; 2010 Dec 09;29(49):6418-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutations in the adenomatous polyposis coli (APC) tumour suppressor are the key initiating event of colorectal cancer.
  • Although the control of WNT signalling is well established as a central tumour-suppressive function, the significance of APC in regulating chromosome instability is less well established.
  • At higher levels of Taxol, APC-deficient cells arrest as efficiently as wild-type cells.
  • Importantly, this dose of Taxol strongly suppresses intestinal tumourigenesis in models of benign (APC(Min/+) mouse) and invasive (AhCreER(+)APC(fl/+)PTEN(fl/fl)) cancer.
  • In contrast to intestinal enterocytes with a general SAC defect because of Bub1 (budding uninhibited by benzimidazole 1) deletion, APC-deficient enterocytes arrest equivalently to wild type when treated with Vinorelbine.
  • This suggests that the failed arrest in response to Taxol is because of a specific defect in microtubule stabilization following Taxol treatment rather than a general role of the APC protein in the mitotic spindle checkpoint.
  • [MeSH-major] Adenomatous Polyposis Coli / drug therapy. Adenomatous Polyposis Coli Protein / physiology. Antineoplastic Agents, Phytogenic / therapeutic use. Drug Resistance, Neoplasm / genetics. Paclitaxel / therapeutic use. Spindle Apparatus / metabolism
  • [MeSH-minor] Animals. Cell Cycle / drug effects. Cell Cycle / genetics. Cell Transformation, Neoplastic / drug effects. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Chromosomal Instability / genetics. Enterocytes / drug effects. Enterocytes / pathology. Male. Mice. Mice, Inbred C57BL. Protein-Serine-Threonine Kinases / genetics. Sequence Deletion. Vinblastine / analogs & derivatives. Vinblastine / therapeutic use. Wnt Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2005 Aug;129(2):626-38 [16083717.001]
  • [Cites] Mol Biol Cell. 2005 Oct;16(10):4609-22 [16030254.001]
  • [Cites] EMBO J. 2006 Jun 21;25(12):2814-27 [16763565.001]
  • [Cites] J Cell Biol. 2007 Jan 15;176(2):183-95 [17227893.001]
  • [Cites] Mol Biol Cell. 2007 Mar;18(3):910-8 [17192415.001]
  • [Cites] Nature. 2007 Apr 5;446(7136):676-9 [17377531.001]
  • [Cites] J Cell Biol. 2007 Sep 24;178(7):1109-20 [17893240.001]
  • [Cites] Dev Cell. 2007 Oct;13(4):566-79 [17925231.001]
  • [Cites] J Cell Biol. 2008 Jun 2;181(5):719-26 [18519734.001]
  • [Cites] Cancer Cell. 2008 Aug 12;14(2):111-22 [18656424.001]
  • [Cites] Mol Cell Biol. 2008 Oct;28(20):6314-28 [18694957.001]
  • [Cites] Nat Genet. 2008 Dec;40(12):1436-44 [19011632.001]
  • [Cites] Cell Motil Cytoskeleton. 2001 May;49(1):1-15 [11309836.001]
  • [Cites] Nat Cell Biol. 2001 Apr;3(4):429-32 [11283619.001]
  • [Cites] Cancer Cell. 2009 Oct 6;16(4):347-58 [19800579.001]
  • [Cites] Nat Cell Biol. 2001 Apr;3(4):433-8 [11283620.001]
  • [Cites] Trends Cell Biol. 2001 Sep;11(9):378-84 [11514192.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):674-81 [12566313.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1236-46 [15131783.001]
  • [Cites] Mol Biol Cell. 2004 Jun;15(6):2978-91 [15075372.001]
  • [Cites] J Cell Biol. 2004 Jun 7;165(5):609-15 [15184397.001]
  • [Cites] Genes Dev. 2004 Jun 15;18(12):1385-90 [15198980.001]
  • [Cites] Nucleic Acids Res. 2004;32(11):e92 [15247325.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Onkologie. 1991 Feb;14(1):7-12 [2057177.001]
  • [Cites] Cancer Res. 1995 Jul 15;55(14):2972-7 [7606712.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1291-4 [7577038.001]
  • [Cites] Science. 1997 Oct 3;278(5335):120-3 [9311916.001]
  • [Cites] Curr Biol. 1998 Oct 22;8(21):1169-78 [9799734.001]
  • [Cites] Cell. 1999 Jan 8;96(1):79-88 [9989499.001]
  • [Cites] J Cell Sci. 2004 Dec 15;117(Pt 26):6339-53 [15561772.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 17;102(20):7286-91 [15857952.001]
  • (PMID = 20729907.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A11243; Canada / Canadian Institutes of Health Research / / 12858; United Kingdom / Cancer Research UK / / 11243; United Kingdom / Cancer Research UK / / ; Canada / Canadian Institutes of Health Research / / 74711; United Kingdom / Cancer Research UK / / A7130; United Kingdom / Cancer Research UK / / 11913
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Antineoplastic Agents, Phytogenic; 0 / Wnt Proteins; 5V9KLZ54CY / Vinblastine; EC 2.7.11.1 / Bub1 protein, mouse; EC 2.7.11.1 / Bub1 spindle checkpoint protein; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; P88XT4IS4D / Paclitaxel; Q6C979R91Y / vinorelbine
  • [Other-IDs] NLM/ PMC3016607; NLM/ UKMS31064
  •  go-up   go-down






Advertisement